摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide | 1356033-60-7

中文名称
——
中文别名
——
英文名称
N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide
英文别名
Panulisib;[8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-1-[6-(2-cyanopropan-2-yl)pyridin-3-yl]-3-methylimidazo[4,5-c]quinolin-2-ylidene]cyanamide
N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide化学式
CAS
1356033-60-7
化学式
C27H20F3N9
mdl
——
分子量
527.511
InChiKey
VJLRLTSXTLICIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    39
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    131
  • 氢给体数:
    1
  • 氢受体数:
    10

SDS

SDS:acb69bad637a3cc618112b0a985afb69
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted imidazoquinoline derivatives as kinase inhibitors
    申请人:Kumar Sanjay
    公开号:US09062046B2
    公开(公告)日:2015-06-23
    The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.
    本发明涉及取代的咪唑并[4,5-c]喹啉衍生物,化合物的公式(I),其中R1、R2、R3、R4、R5、R6和R7在规范中定义,它们的制备过程,包括公式(I)化合物的制药组合物和它们在治疗由一个或多个激酶介导的疾病或紊乱,特别是增殖性疾病或紊乱,如癌症中的用途。这些化合物也可用于治疗炎症性疾病和血管生成相关紊乱。
  • SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS
    申请人:Kumar Sanjay
    公开号:US20130116248A1
    公开(公告)日:2013-05-09
    The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.
    本发明涉及取代的咪唑[4,5-c]喹啉衍生物,化合物的公式为(I),其中R1、R2、R3、R4、R5、R6和R7如规范中所定义,制备它们的方法,包括化合物(I)的药物组合物,以及它们在治疗由一个或多个激酶介导的疾病或紊乱中的应用,特别是增殖性疾病或紊乱,如癌症。这些化合物也可用于治疗炎症性疾病和血管生成相关紊乱。
  • [EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, INTERMEDIATES AND POLYMORPHS THEREOF<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE COMPOSÉS D'IMIDAZO[4,5-C]QUINOLINE SUBSTITUÉS, D'INTERMÉDIAIRES ET DE POLYMORPHES DE CEUX-CI
    申请人:PIRAMAL ENTPR LTD
    公开号:WO2015145369A1
    公开(公告)日:2015-10-01
    The present invention relates to a process for preparation of substituted imidazo[4,5- c]quinoline compounds (the compounds of formula I as described) and intermediates thereof. The present invention also relates to polymorphs of a compound encompassed in the compound of formula I and their use in the treatment of proliferative disorders, particularly cancers.
    本发明涉及一种制备取代咪唑并[4,5-c]喹啉化合物(如所述的化合物I的化合物)及其中间体的方法。本发明还涉及化合物I中包含的化合物的多晶形态及其在治疗增殖性疾病,特别是癌症中的应用。
  • [EN] SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOQUINOLINE SUBSTITUÉS À TITRE D'INHIBITEURS DE KINASES
    申请人:PIRAMAL LIFE SCIENCES LTD
    公开号:WO2012007926A1
    公开(公告)日:2012-01-19
    The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1 R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.
    本发明涉及取代咪唑并[4,5-c]喹啉衍生物,化合物的化学式为(I),其中R1、R2、R3、R4、R5、R6和R7如规范中定义,其制备方法,包括化合物(I)的药物组合物,以及它们在治疗由一个或多个激酶介导的疾病或紊乱中的用途,特别是增殖性疾病或紊乱,如癌症。这些化合物还可用于治疗炎症性疾病和与血管生成相关的紊乱。
查看更多